Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131490 | 1.00 | BTK (0.56) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL4533054 | 1.00 | BTK (0.56) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL31246148 | 0.98 | BTK (0.54) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL31246132 | 0.98 | BTK (0.54) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL18696405 | 0.98 | BTK (0.54) | BTKCTSKGAAKMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29424919 | 0.98 | BTK (0.54) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL23620440 | 0.91 | BTK (0.49) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL31072094 | 0.88 | BTK (0.50) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL17413388 | 0.88 | BTK (0.56) | BTKCTSKGAAKMT2AL3MBTL1 | |
| SCHEMBL17398093 | 0.88 | BTK (0.56) | BTKCTSKGAAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4714952-A1 | COMPOUND AND USE THEREOF | Autobio Group Co., Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | BRIDGENE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006040281-A1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-5567726-A | SELECTIVE AGONISTS OF 5-HYDROXYTRYPTAMINE-LIKE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | MERCK, SHARP & DOHME LTD. (GB) | 1996-10-22 | — | — | US | disclosed |
| WO-1994002477-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | CDK1, MAPK1, NFATC1 | BTK 454/4885CTSK 2137/4885GAA 1575/4885 |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | YAP1, TEAD1, TEAD2 | BTK 3038/4885CTSK 4294/4885GAA 4597/4885 |
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | BTK 3691/4885CTSK 3578/4885GAA 4000/4885 |
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | BTK 1649/4885CTSK 3810/4885GAA 2625/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | BTK 3266/4885CTSK 3740/4885GAA 4098/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | BTK 3679/4885CTSK 3486/4885GAA 4018/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | BTK 3873/4885CTSK 3283/4885GAA 4837/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | BTK 1991/4885CTSK 2282/4885GAA 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.